November 17, 2022
A throng of new medicines hit the Japanese market on November 16 upon their NHI reimbursement listing, including Bristol Myers Squibb’s Sotyktu (deucravacitinib) and Boehringer Ingelheim’s Spevigo (spesolimab), both psoriasis therapies. An oral tyrosine kinase 2 (TYK2) inhibitor, Sotyktu is...read more